Basilea Launches Complementary Phase III Trial For Anti-infective Candidate
This article was originally published in The Pink Sheet Daily
New trial adds to data on isavuconazole for invasive yeast and mold infections.
You may also be interested in...
Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.
To help patients suffering from cardiorenal syndrome, an undertreated illness, Procyrion has embarked on the first in-human trials of its Aortix mechanical circulatory support device.
NIH director Francis Collins and former FDA commissioner Margaret Hamburg outline learnings from the COVID-19 pandemic and what needs to be done next amid concerns around the dangerous Delta and also Lambda variants. They also discuss the role of the WHO, which has “many masters to try and satisfy.”